Stockscreener 앱 받기
2.10
4.55%
-0.10
시간 외 거래:
2.00
-0.10
-4.76%
전일 마감가:
$2.20
열려 있는:
$2.1996
하루 거래량:
76,207
Relative Volume:
2.75
시가총액:
$1.24M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.76%
1개월 성능:
-52.83%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.00
$2.1999
1주일 범위
$1.80
$2.3714
52주 변동 폭
$1.80
$12.48
Naya Biosciences Inc Stock (NAYA) Company Profile
명칭
Naya Biosciences Inc
전화
(978) 878-9505
주소
5582 BROADCAST COURT, SARASOTA
NAYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAYA
Naya Biosciences Inc
|
2.10 | 1.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Naya Biosciences Inc 주식(NAYA)의 최신 뉴스
NAYA Biosciences Delays 2024 Yearly Report Filing - TipRanks
Bifunction conjunction afoot; multiple players competing - BioWorld MedTech
NAYA Biosciences to effect 1-for-12 reverse split - TipRanks
NAYA Biosciences announces 1-for-12 reverse stock split By Investing.com - Investing.com Australia
NAYA Biosciences announces 1-for-12 reverse stock split - Investing.com India
NAYA Biosciences Announces 1-for-12 Reverse Stock Split Effective March 18, 2025 - Nasdaq
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025 - GlobeNewswire
NAYA stock touches 52-week low at $0.33 amid market challenges - Investing.com
NAYA Biosciences Supports U.S. Executive Order to Increase Access and Affordability of IVF Services - Nasdaq
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment - The Manila Times
NAYA Biosciences nominates five candidates for the Board - TipRanks
NAYA Biosciences Announces Nomination of New Board Members - GlobeNewswire
Maxim Group Upgrades NAYA Biosciences (NAYA) - MSN
NAYA Stock Hits 52-Week Low at $0.35 Amid Market Challenges - MSN
NAYA Biosciences (NASDAQ:NAYA) Raised to Buy at Maxim Group - Defense World
NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues - TipRanks
NAYA Biosciences sets public offering at $0.70 per unit By Investing.com - Investing.com South Africa
Lakewood Ranch life sciences firm seeks to raise $9.5M through public offering - Business Observer
NAYA Stock Hits 52-Week Low at $0.62 Amid Market Challenges - Investing.com
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering - GlobeNewswire
NAYA Biosciences sets public offering at $0.70 per unit - Investing.com
NAYA Biosciences Raises $9.5M in Public Offering to Fund Acquisition and Growth Plans - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NAYA Biosciences expands oncology pipeline with new antibody By Investing.com - Investing.com Nigeria
NAYA Biosciences expands oncology pipeline with new antibody - Investing.com
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody - GlobeNewswire
NAYA Biosciences Unveils NY-500, AI-Enhanced Cancer Antibody Outperforming Keytruda - StockTitan
NAYA (NAYA Biosciences) Long-Term Debt & Capital Lease Obli - GuruFocus.com
The horror of Saydnaya jail, symbol of Assad excesses - News- Graphic
INVO Bioscience : Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System - Marketscreener.com
NAYA Biosciences files to sell $10M of units - Nasdaq
Grapevine December 15, 2024: Changing of the guard - The Jerusalem Post
NAYA Biosciences Inc. (NAYA) reports earnings - Quartz
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
Naya Biosciences Inc (NAYA) 재무 분석
Naya Biosciences Inc (NAYA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):